Your browser doesn't support javascript.
loading
Five-year survival in patients with nodular and superficial spreading melanomas in the US population.
Allais, Blair S; Beatson, Meghan; Wang, Hongkun; Shahbazi, Shandiz; Bijelic, Lana; Jang, Sekwon; Venna, Suraj.
Afiliação
  • Allais BS; Washington University Department of Dermatology, Washington, DC. Electronic address: blairallais@gwu.edu.
  • Beatson M; Memorial Sloan Kettering Cancer Center Department of Medicine, New York, NY.
  • Wang H; Georgetown University Departments of Biostatistics, Bioinformatics, and Biomathematics, Washington, DC.
  • Shahbazi S; Georgetown University Departments of Medicine, Washington, DC.
  • Bijelic L; Hospital de Sant Joan Despi Moises Broggi, Barcelona, Spain.
  • Jang S; University of Virginia School of Medicine, Charlottesville, VA; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, VA.
  • Venna S; University of Virginia School of Medicine, Charlottesville, VA; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, VA.
J Am Acad Dermatol ; 84(4): 1015-1022, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33253834
ABSTRACT

BACKGROUND:

Although superficial spreading melanomas (SSM) are diagnosed as thinner lesions, nodular melanomas (NM) have a more rapid growth rate and are biologically more aggressive compared with other histologic subtypes.

OBJECTIVE:

To determine the difference in 5-year relative survival in patients with NM and SSM at the same Breslow depth and TNM stage.

METHODS:

A population-based cross-sectional analysis compared the 5-year relative survival of patients with NM and SSM using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)∗Stat software (version 8.2.1-8.3.5). Chi-square tests compared the proportions, and Kaplan-Meier method with Z-score compared 5-year relative survival.

RESULTS:

For patients receiving a diagnosis between 2004 and 2009, 5-year relative survival was lower in NM compared with SSM (53.7% vs 87.3%; Z score, -41.35; P < .001). Similarly, for patients receiving a diagnosis between 2010 and 2015, 5-year relative survival was lower in NM compared with SSM (61.5% vs 89.7%; Z score, -2.7078; P < .01). Subgroup analyses showed inferior survival in NM in T1b, and survival differences remained significant after excluding patients with nodal or distant metastases.

CONCLUSIONS:

Five-year relative survival is worse in NM compared with SSM especially in T1b, T2a, and T2b melanomas. Melanoma subtype should be taken into consideration when making treatment recommendations.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article